← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Sanaria, Inc.
Rockville, MD
$112,853,639
Total funding
51
Grants
Funding over time
peak $10.9M · FY2005–25$20M$15M$10M$5M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$112,853,639 · 51
By mechanism
R44$69,755,488 · 13
R43$16,519,304 · 28
SB1$11,865,596 · 4
U01$11,430,401 · 3
U44$2,984,254 · 2
N43$298,596 · 1
Investigators at Sanaria, Inc.
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Emerging Leaders
6–10 yrs in
Not enough data
Largest grants
Expanding the breadth, magnitude, and durability of PfSPZ vaccines by creating multi-strain vaccines, designer hybrid and genetically altered parasite vaccines and use of a unique adjuvant.$1,315,127
U01 · FY2021 · AI
Expanding the breadth, magnitude, and durability of PfSPZ vaccines by creating multi-strain vaccines, designer hybrid and genetically altered parasite vaccines and use of a unique adjuvant.$1,279,157
U01 · FY2022 · AI
Expanding the breadth, magnitude, and durability of PfSPZ vaccines by creating multi-strain vaccines, designer hybrid and genetically altered parasite vaccines and use of a unique adjuvant.$1,243,700
U01 · FY2023 · AI
Expanding the breadth, magnitude, and durability of PfSPZ vaccines by creating multi-strain vaccines, designer hybrid and genetically altered parasite vaccines and use of a unique adjuvant.$1,083,506
U01 · FY2024 · AI
Expanding the breadth, magnitude, and durability of PfSPZ vaccines by creating multi-strain vaccines, designer hybrid and genetically altered parasite vaccines and use of a unique adjuvant.$1,012,212
U01 · FY2025 · AI
Universal Attenuated Sporozoite Vaccine and Challenge System$1,000,000
R44 · FY2013 · AI
A glycolipid adjuvant to promote dose sparing, accelerate immunization schedules and extend durability of high-level protection with a live attenuated sporozoite malaria vaccine$1,000,000
R44 · FY2018 · AI
In-Vitro Culture of Plasmodium falciparum Sporozoites for Malaria Vaccine$1,000,000
R44 · FY2020 · AI
IMPROVING MANUFACTURING AND POTENCY OF CRYOPRESERVED MALARIA SPOROZOITE VACCINE$1,000,000
R44 · FY2014 · AI
Universal Attenuated Sporozoite Vaccine and Challenge System$1,000,000
R44 · FY2012 · AI
A Unique Automated Bioreactor for Rearing Aseptic Mosquitoes from Larvae to Adults to Support Manufacture of Sanaria PfSPZ Products$1,000,000
R44 · FY2022 · AI
Transgenic Mosquitoes for Improved Malaria Sporozoite Vaccine Manufacture$1,000,000
R44 · FY2013 · AI
Automating mosquito microdissection for a malaria PfSPZ vaccine$1,000,000
R44 · FY2021 · AI
A glycolipid adjuvant to promote dose sparing, accelerate immunization schedules and extend durability of high-level protection with a live attenuated sporozoite malaria vaccine$1,000,000
R44 · FY2017 · AI
IMPROVING MANUFACTURING AND POTENCY OF CRYOPRESERVED MALARIA SPOROZOITE VACCINE$1,000,000
R44 · FY2013 · AI
Universal Attenuated Sporozoite Vaccine and Challenge System$1,000,000
R44 · FY2014 · AI
A glycolipid adjuvant to promote dose sparing, accelerate immunization schedules and extend durability of high-level protection with a live attenuated sporozoite malaria vaccine$1,000,000
R44 · FY2016 · AI
A Unique Automated Bioreactor for Rearing Aseptic Mosquitoes from Larvae to Adults to Support Manufacture of Sanaria PfSPZ Products$1,000,000
R44 · FY2021 · AI
IMPROVING MANUFACTURING AND POTENCY OF CRYOPRESERVED MALARIA SPOROZOITE VACCINE$1,000,000
R44 · FY2012 · AI
A Unique Automated Bioreactor for Rearing Aseptic Mosquitoes from Larvae to Adults to Support Manufacture of Sanaria PfSPZ Products$1,000,000
R44 · FY2023 · AI